Pipeline
| Disease Area | Indication | Target factor | Seed | Pre-Clinical | Phase I |
|---|---|---|---|---|---|
| Local tissue regeneration | |||||
| Osteo arthritis | |||||
| mRNA: RUNX1 | |||||
| Partner: Axcelead Inc. | |||||
| Skin | |||||
| mRNA: F | |||||
| Ocular | |||||
| mRNA: C | |||||
| Otolaryngological | |||||
| mRNA: D | |||||
| Vaccine | |||||
| Immune | |||||
| mRNA: B | |||||
| Partner: Kao Corporate | |||||
| Infection | |||||
| mRNA: A | |||||
| Partner: Crafton Biotechnology / MAB | |||||
| Oncology | |||||
| mRNA: E | |||||
| Oncology | |||||
| GBM | |||||
| ASO: TUG1 | |||||
| Partner: NAGOYA University | |||||
| HER2-negative breast cancer |
|||||
| siRNA: PRDM14 | |||||
| Partner: Keio University | |||||